by Madaline Spencer and Scott Harwood | Sep 16, 2026
Karen A. Jones, EdD, President and CEO of wAIHA Warriors, discusses the approval of Imaavy (nipocalimab) and its impact on patients with warm autoimmune hemolytic anemia (wAIHA). wAIHA is a rare hematologic autoimmune condition characterized by antibodies that...
by Madaline Spencer and Scott Harwood | Aug 26, 2026
The US Food and Drug Administration (FDA) has approved Imaavy (nipocalimab) for the treatment of patients ages 12 years and older with warm autoimmune hemolytic anemia (wAIHA) who are currently or previously treated with corticosteroids. wAIHA is a rare hematologic...
by CheckRare Staff and Scott Harwood | Jul 24, 2026
H. Miles Prince, MD, MBBS, Professor at the University of Melbourne, Australia, and Director, Peter MacCallum Cancer Center, and Director of Molecular Oncology and Cancer Immunology, Epworth HealthCare, describes the objectives and results of a new investigation which...
by Madaline Spencer and Scott Harwood | Mar 6, 2026
John Taggart, Head of Communications at Niemann-Pick UK (NPUK), discusses the ASMD Perspective Index and its use in diagnosing Niemann-Pick disease. Niemann-Pick disease is an inherited condition characterized by abnormal lipid metabolism that causes harmful...
by Madaline Spencer and Scott Harwood | Mar 5, 2026
Bob Stevens, Group CEO of the MPS Society and Rare Disease Research Partners in the UK, discusses global efforts towards developing treatment options for patients with rare lysosomal storage disorders (LSDs). Mr. Stevens has been involved with the UK MPS...
